INSTRUCTIONS: For more complete instructions and definitions, refer to the user guide at: www.phac-aspc.gc.ca/im/aefi-form-eng.php

Report events which have a temporal association with a vaccine and which cannot be clearly attributed to other causes. A causal relationship does not need to be proven, and submitting a report does not imply causality.

Of particular interest are those AEFIs which:

- a) Meet one or more of the seriousness criteria
- b) Are unexpected regardless of seriousness

Refer to the user guide, Background Information and for additional clarification.

NOTE:

- · The numbers below correspond to the numbered sections of the form.
- All dates should be captured in the following format: YYYY / MM / DD.
- When reporting an AEFI, check one of the boxes on the top right hand corner of the first page of the AEFI form to indicate whether it is an INITIAL or FOLLOW UP report. For all follow up reports, please specify the UNIQUE EPISODE NUMBER.
 - 1a) The UNIQUE EPISODE NUMBER is assigned by the Province/Territory. Leave it blank unless authorized to assign it.
 - 1b) The REGION NUMBER is a number that corresponds to a given health unit. Leave it blank if it doesn't apply to your locale.
 - 2) The **IMPACT LIN** is assigned by IMPACT nurse monitors (LIN: Local Inventory Number).
 - 3) The information provided in this section is confidential and should not be sent to the Public Health Agency of Canada.
 - 4a) Indicate the Province/Territory where the vaccine was administered, abbreviations may be used.
 - 4c) Provide all information as requested in the table. For the "Dose #", provide the number in series (1, 2, 3, 4, or 5) if known. For the Influenza vaccine, unless a patient receives two doses in one season, the "Dose #" should be recorded as "1".
 - 7a) Indicate the highest impact of the AEFI on the patient's daily activities as assessed by the patient or the parent/caregiver.
 - 7c) Provide details of any investigations or treatments in section 10. If the patient was already in hospital when immunized and the immunization resulted in a longer hospital stay, indicate "Resulted in prolongation of existing hospitalization" and provide the number of days by which the patient's hospital stay was prolonged. For all hospitalizations, indicate the date of admission and discharge.
 - 8) MOH/MHO: Medical Officer of Health, MD: Medical Doctor, RN: Registered Nurse.
 - 9) Choose, from section 9 (AEFI details), the description that best fits the AEFI being reported. Make sure to record the time of onset and duration of signs/symptoms using the most appropriate time unit: Days, Hours or Minutes. Provide additional details of any investigation, therapy, and other information as appropriate in section 10.
 - 11) This section is to be completed by the MOH/MHO, MD, RN or their designate who are assigned to provide public health recommendations according to the P/T best practices.
 - 12) Information in this section is not collected by all P/Ts.

RETURN COMPLETED FORM TO YOUR LOCAL PUBLIC HEALTH UNIT ADDRESS AT:

Alberta (AB) Northwest Territories (NT) Quebec (QC)
British Columbia (BC) Nova Scotia (NS) Saskatchewan (SK)

Manitoba (MB) Nunavut (NU) Yukon (YT)

New Brunswick (NB) Ontario (ON) Canadian Forces Health Services (CFHS)
Newfoundland and Labrador (NL) Prince Edward Island (PE) Public Health Agency of Canada (PHAC)



Initial report

Follow up report (Unique episode number)

1a) UNIQUE EPISODE NUMBI	ER:	1b) REGION NUMBER:			2) IMPACT LIN:				
3) PATIENT IDENTIFICATION									
First name:	Last name:			Health	Health number:				
Address of usual residence:									
Province/Territory:		Postal code:		Phone: ()		(ext.)	
Information Source: First name:		Last name:			Rela	tion to patient:			
Contact info, if different:									
4) INFORMATION AT TIME OF	IMMUNIZATION AND AEF	I ONSET							
·				4b) Medical history (up to the time of AEFI onset) (Check all that apply and provide details in section 10) Concomitant medication(s) Known medical conditions/allergies Acute illness/injury					
4c) Immunizing agent	Trade name	Manufacturer	Lot	number	Dose #	Dosage/unit	Route	Site	
						1			
						1			
						1			
						1			
						1			
5) IMMUNIZATION ERRORS				6) PREVIOUS AEFI					
Did this AEFI follow an incorrect immunization? No Unknown Yes (If Yes, choose all that apply and provide details in section 10) Given outside the recommended age limits Product expired Incorrect route Wrong vaccine given Dose exceeded that recommended for age Other, specify:				Did an AEFI follow a previous dose of any of the above immunizing agents (Table 4c)? (Choose one of the following) No Yes (Provide details in section 10) Unknown Not applicable (no prior doses)					
7) IMPACT OF AEFI, OUTCOM	ME, AND LEVEL OF CARE O)BTAINED							
7a) Highest impact of AEFI: (Choose one of the following) Did not interfere with daily activities Interfered with but did not prevent daily activities				7b) Outcome at time of report: Death Date (Y/M/D): Permanent disability/incapacity Not yet recovered The state of report: Not yet recovered					
Prevented daily activities				Fully recovered Unknown †(Provide details in section 10)					
7c) Highest level of care obtained: (Choose one of the following) Unknown None Telephone advice from a health professional Non-urgent visit Emergency visit Required hospitalization (days) OR Resulted in prolongation of existing hospitalization (bydays) Date of hospital admission: (Y/M/D):									
8) REPORTER INFORMATION									
Setting: Physician office	Public health I	Hospital Other,	, specify:						
Name:			Phone: ()	(ext.	,) Fax: ()			
Address:				City:					
Province/Territory:			Postal code:	Date i	reported: (Y /	M / D):			
Signature:		MD RN	IMPACT	Other, specify:					

UNIQUE EPISODE NUMBER:		REGION NUMBER:	IMPACT LIN:					
9) AEFI DETAILS: Complete all sections as appropriate; for each, check all signs/symptoms that apply. Item(s) with asterisk (*) should be diagnosed by a physician. If not, provide sufficient information to support the selected item(s). Use SECTION 10 for additional information including, clinical details and test results.								
9a) Local reaction at or near vaccination site		Interval: → Min Hrs Duration: → Min Hrs	Days from immunization to onset of 1st symptom or sign Days from onset of 1st symptom/sign to resolution of all symptoms/signs					
Infected abscess Sterile abscess		Cellulitis Nodule Rea	ction crosses joint Lymphadenitis Other, specify:					
For any vaccination site reaction indicated about Swelling Pain Tenderness Site(s) of reaction (e.g. LA, RA) Spontaneous/surgical drainage		Erythema Warmth Ind Palpable fluctuance Flu	provide details in section 10: duration Rash Largest diameter of vaccination site reaction: cm uid collection shown by imaging technique (e.g. MRI, CT, ultrasound) mphangitic streaking Regional lymphadenopathy					
9b) Allergic and Allergic-like events		Interval: → Min Hrs Days from immunization to onset of 1st symptom or sign Duration: → Min Hrs Days from onset of 1st symptom/sign to resolution of all symptoms/signs						
Chose one of the following:	Anaphylaxis	Oculo-Respiratory Syndrome (OR	S) Other allergic events					
	Urticaria	ria Erythema Pruritus Prickle sensation Rash (For these events, specify site of reaction)						
Skin/mucosal	Angioedema: Eyelids	Tongue Throat Face Limbs	Uvula Larynx Lip Eye(s): Red bilateral Red unilateral Itchy					
Cardio-vascular	Measured hypotension ↓ central pulse volume Capillary refill time >3 sec Tachycardia ↓ or loss of consciousness (Duration):							
Respiratory	ce Sensation of throat closure Stridor Dry cough etractions Grunting Cyanosis Sore throat eathing Chest tightness							
Gastrointestinal	Diarrhea	Abdominal pain Nausea	Vomiting					
9c) Neurologic events Interval: →MinHrsDays from immunization to onset of 1st symptom or sign Duration: →MinHrsDays from onset of 1st symptom/sign to resolution of all symptoms/s								
Meningitis* Encephalopathy/Encephalitis* Guillain-Barré Syndrome (GBS)* Bell's Palsy* Other paralysis* Seizure Other neurologic diagnosis*, <i>specify:</i>								
Seizure details: Witnessed b Sudden loss Generalized	abnormality by healthcare p s of consciousr	rofessional Yes No ness Yes No Tonic Clonic Tonic-clonic	ging abnormality Brain/spinal cord histopathologic abnormality Unknown Unknown Atonic Absence Myoclonic) <i>OR</i> Partial					
9d) Other events		Interval: → Min Hrs Days from immunization to onset of 1st symptom or sign Duration: → Min Hrs Days from onset of 1st symptom/sign to resolution of all symptoms/signs						
Hypotonic-Hyporesponsive Episode (age <2 years)			Rash (Non-allergic) Generalized Localized (Site)					
Persistent crying (Continuous		esponsiveness/unresponsiveness erying for ≥3 hours)	Thrombocytopenia* Platelet count <150x10 ⁹ /L Petechial rash Other clinical evidence of bleeding					
Intussusception* Anaesthesia/Paraesthesia Numbness Tingling Burning								
Arthritis Joint redness Inflammatory changes in syr		arm to touch Joint swelling	Formication Other, specify: Generalized Localized (Site)					
Parotitis (Parotid gland swelling with pain and/or tenderness) Fever ≥38.0°C (Note: report ONLY if fever occurs in conjunction with a reportable event. For fever in a neurological event, use Section 9c)								
Other serious or unexpected event(s) not listed in the form (Specify and provide details in Section 10)								

UNIQUE EPISODE NUMBER:	REGION NUMBER:	IMPACT LIN:
10) SUPPLEMENTARY INFORMATION (Please indicate the silf not, provide sufficient information to support the selected	section number when providing details. Please provide details of any ord item(s).	investigation or treatment for the recorded AEFI).
11) RECOMMENDATIONS FOR FURTHER IMMUNIZATION (Provide comments, use section 10 if extra space needed		
No change to immunization schedule	Controlled setting for next immunization	Other, specify:
Expert referral, specify:	No further immunizations with:, specify:	
Determine protective antibody level	Active follow up for AEFI recurrence after next vaccine	
Name:	Othor was if a	
Professional status: MOH/MHO MD RN COMMENTS:	Other, specify:	
COMINENTS.		
Phone: () (ext.) Date: (Y / M / D): Signatur	e:
12) FOLLOW UP INFORMATION FOR A SUBSEQUENT DO	OSE OF SAME VACCINE(S) (Provide details in section 10)	
Vaccine administered without AEFI Vaccine ad	dministered with recurrence of AEFI Vaccine administer	ed, other AEFI observed